Background: Breast cancer is the fourth leading cause of death and disability in the Eastern
Mediterranean Region (‎ EMR)‎; although the incidence is lower than in the developed …

Approximately 6% of metastatic breast cancers arise de novo. While systemic therapy (ST)
remains the treatment backbone as for patients with metachronous metastases, locoregional …

We used to LASSO-Cox method for determining prognostic factors of male breast cancer
survival and showed the superiority of this method compared to Cox proportional hazard …

Prognostic factors in male breast cancer (MaBC) are controversial. The objective of this
study was to analyze patient characteristics and prognostic factors in MaBC over the last …

Background Male breast cancer (MBC) is a rare disease, accounting for< 1% of all male
carcinomas. Lack of prospective data, the current therapy for MBC is based on retrospective …

Aim Male breast cancer (MBC) is a rare disease and recommendations for its clinical
management are often extrapolated from those for female breast cancer, even if breast …

Background: Male breast cancer accounts for less than 1% of all cancers found in men. It
usually presents at a later age and stage as compared to female breast cancer. Treatment …

Results: The median age of patients was 59 years. Only 3 (7.7%) patients had positive family
history. All patients presented by breast swellings that were associated with axillary mass in …

Background Male breast cancer (MBC) is an uncommon malignancy with an incidence that
accounts for about 1% of all breast cancer cases. It commonly presents as a locally …

Compared with female breast cancer, male breast cancer is a rare disease, and the
relationship between clinical/pathologic features and prognosis is controversial, or even …